Today: 29 April 2026
Australian mortgage brokers end 2025 with rate cuts, bank shake-ups and an AI push — here’s what stood out
31 December 2025
1 min read

Australian mortgage brokers end 2025 with rate cuts, bank shake-ups and an AI push — here’s what stood out

NEW YORK, December 31, 2025, 03:55 ET

  • Australian mortgage-broking leaders closed out 2025 pointing to falling rates and record broker market share as tailwinds.
  • Major banks’ policy moves on company and trust lending and a stepped-up compliance focus kept brokers busy into year-end.
  • Podcast listening trends in the sector tracked the same themes: technology, broker relevance, and what comes next for housing.

Australian mortgage brokers wrapped up 2025 with momentum from falling interest rates and a growing share of home-loan origination, even as bank rule changes and regulators’ scrutiny kept the sector on its toes.

Mortgage Professional Australia said the October-to-December quarter was one of the year’s most unpredictable stretches, marked by “shock lending decisions” and fresh regulatory pressure alongside shifting Reserve Bank of Australia expectations. https://www.mpamag.com/au/news/general/202…

Why it matters now: brokers are heading into 2026 with more borrowers shopping around as rates ease, but also with lenders tightening policies in pockets of the market that can quickly reroute deal flow.

It also matters because the battleground is changing. Banks are investing more heavily in proprietary channels — direct-to-bank distribution — while the broker channel argues it remains central to competition and access, especially for complex borrowers.

MPA pointed to long-running frictions that stayed in play through 2025, including clawbacks — when a lender seeks to recover broker commissions after early loan repayment — and “channel conflict,” the industry shorthand for tensions when lenders prioritize direct channels over third-party brokers.

The publication said year-end action included a major proprietary lending push by ANZ and decisions by some major lenders to restrict company and trust lending, a segment popular with certain investors and small-business borrowers.

Regulators also featured prominently in the final quarter, with MPA highlighting heightened attention on higher-risk lending and private credit — typically non-bank lending that sits outside traditional bank balance sheets but has been expanding globally.

At the same time, industry media coverage portrayed 2025 as a year of strong broker performance, with MPA citing record-high broker market share in home lending and broader visibility in commercial finance.

Those themes carried into audio, too. Broker Daily said its most popular podcasts of 2025 focused on falling rates, record broker market share and the growing role of artificial intelligence in broking workflows.

Episodes highlighted lenders’ technology strategies and debated whether brokers remain relevant as AI tools improve — a question that has started showing up not just in fintech circles, but in mainstream mortgage distribution planning.

Broker Daily also flagged post-election housing policy as a key uncertainty for 2026, reflecting industry focus on how government decisions can alter demand, affordability, and lending settings.

Stock Market Today

  • Align Technology Beats Q1 Sales Estimates, Reports $1.04 Billion Revenue
    April 29, 2026, 4:41 PM EDT. Align Technology (NASDAQ:ALGN) reported a strong Q1 CY2026 with 6.2% year-on-year sales growth to $1.04 billion, exceeding Wall Street revenue estimates by 1.8%. Adjusted earnings per share came in at $2.58, 12.8% above analyst consensus. The company's operating income also beat expectations by 11.1%, driven by solid operating margins of 21.5%. Despite these gains, Align projected next quarter revenue around $1.05 billion, aligning with market forecasts. The company's five-year annualized revenue growth of 7.8% outpaces healthcare sector averages, but recent two-year growth has slowed to 2.3%, raising concerns about demand trends. Analysts project modest growth going forward, around 3%, indicating cautious investor sentiment on new product impact.

Latest article

Nebius Stock Jumps as Meta’s AI Spending Reset Puts $27 Billion Deal in Focus

Nebius Stock Jumps as Meta’s AI Spending Reset Puts $27 Billion Deal in Focus

29 April 2026
Nebius Group N.V. shares rose 5.3% to $142.73 Wednesday as Meta Platforms raised its 2026 capital spending forecast by up to $10 billion, citing higher data center costs. Nebius has a contract to supply Meta with up to $27 billion in AI cloud capacity. Fourth-quarter 2025 revenue jumped 547% to $227.7 million, but the company reported a net loss of $249.6 million.
Phillips 66 Stock Jumps as Surprise Profit Shows Refining Margins Are Back in Focus

Phillips 66 Stock Jumps as Surprise Profit Shows Refining Margins Are Back in Focus

29 April 2026
Phillips 66 reported an adjusted first-quarter profit of $200 million, or 49 cents per share, beating analyst forecasts of a loss. Strong refining margins and 95% plant utilization offset $839 million in hedge-related losses. Shares rose over 6% after the results. The company also completed its acquisition of Lindsey Oil Refinery assets in the UK.
Extreme Networks Stock Jumps as Q3 Earnings Beat Puts Cisco, HPE Rivals in Focus

Extreme Networks Stock Jumps as Q3 Earnings Beat Puts Cisco, HPE Rivals in Focus

29 April 2026
Extreme Networks shares surged 28% after reporting fiscal Q3 revenue of $316.9 million, up 11%, and non-GAAP earnings of 26 cents per share, both above estimates. The company forecast Q4 revenue of $330–$335 million, topping FactSet’s $326.9 million estimate. SaaS annual recurring revenue rose 28.6% to $236.4 million. Net income climbed to $10.6 million from $3.5 million a year earlier.
Al-Arafah Islami Bank, Provati Insurance sign deal to digitise premium payments in Bangladesh
Previous Story

Al-Arafah Islami Bank, Provati Insurance sign deal to digitise premium payments in Bangladesh

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades
Next Story

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Go toTop